T1	Participants 268 280	236 patients
T2	Participants 576 599	71 patients (1981-1983)
T3	Participants 797 830	survival of PAN and CSS patients.
T4	Participants 925 953	patients without HBV markers
T5	Participants 972 998	patients with HBV markers.
T6	Participants 1002 1034	78 patients without HBV markers,
T7	Participants 1124 1160	33 patients with PAN related to HBV,
T8	Participants 1470 1536	56 patients and addressed to severe PAN without HBV markers or CSS